Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Large genome-wide association studies of glycemic traits have identified genetics variants that are associated with insulin resistance (IR) in the general population. It is unknown whether people with genetic enrichment for these IR variants respond differently to interventions that aim to improve insulin sensitivity. We built a genetic risk score (GRS) based on 17 established IR variants and effect sizes (weighted IR-GRS) in 2,713 participants of the Diabetes Prevention Program (DPP) with genetic consent. We tested associations between the weighted IR-GRS and insulin sensitivity index (ISI) at baseline in all participants, and with change in ISI over 1 year of follow-up in the DPP intervention (metformin and lifestyle) and control (placebo) arms. All models were adjusted for age, sex, ethnicity, and waist circumference at baseline (plus baseline ISI for 1-year ISI change models). A higher IR-GRS was associated with lower baseline ISI (β = −0.754 [SE = 0.229] log-ISI per unit, P = 0.001 in fully adjusted models). There was no differential effect of treatment for the association between the IR-GRS on the change in ISI; higher IR-GRS was associated with an attenuation in ISI improvement over 1 year (β = −0.520 [SE = 0.233], P = 0.03 in fully adjusted models; all treatment arms). Lifestyle intervention and metformin treatment improved the ISI, regardless of the genetic burden of IR variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 1×
“01].(11) We estimated the insulin response by the insulinogenic index using the formula [(insulin at 30 min)-(insulin at 0 min)] / [(glucose at 30 min)-(glucose at 0 min)].”
MethodReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“The diagnosis of diabetes was defined according to American Diabetes Association guidelines as a fasting glucose above ≥126 mg/dL or 2-h glucose ≥200 mg/dL during the OGTT, which were confirmed on a second test within 6 weeks.(10)”
MethodKahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166 · cited 7×
“We have previously shown that a GRS derived from established T2D variants predict diabetes incidence in DPP participants (15); in contrast, our IR-GRS was not associated with diabetes incidence in the current analyses.”
ResultSelf-citationNew genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk
DIAGRAM Consortium, Dupuis, J., GIANT Consortium, Global BPgen Consortium, Anders Hamsten on behalf of Procardis Consortium, the MAGIC investigators, Langenberg, C., Prokopenko, I., Saxena, R., Soranzo, N., et al. (2010) · Nature Genetics · doi:10.1038/ng.520 · Cited by 2,166 · cited 4×
“investigators.(5-7) We did not include TCF7L2, as the association of the T2D risk allele with lower FI is considered to be an artifact of ascertainment driven by the determination of this”
InfluentialScott, R. A., Lagou, V., Welch, R. P., Wheeler, E., Montasser, M. E., Luan, J., Mägi, R., Strawbridge, R. J., Rehnberg, E., Gustafsson, S., et al. (2012) · Nature Genetics · doi:10.1038/ng.2385 · Cited by 828 · cited 4×
“investigators.(5-7) We did not include TCF7L2, as the association of the T2D risk allele with lower FI is considered to be an artifact of ascertainment driven by the determination of this”
BackgroundResultManning, A. K., Hivert, M.-F., Scott, R. A., Grimsby, J. L., Bouatia-Naji, N., Chen, H., Rybin, D., Liu, C.-T., Bielak, L. F., Prokopenko, I., et al. (2012) · Nature Genetics · doi:10.1038/ng.2274 · Cited by 827 · cited 4×
“investigators.(5-7) We did not include TCF7L2, as the association of the T2D risk allele with lower FI is considered to be an artifact of ascertainment driven by the determination of this”
BackgroundResultSelf-citation(1999) · Diabetes Care · doi:10.2337/diacare.22.4.623 · Cited by 725
Utzschneider, K. M., Prigeon, R. L., Faulenbach, M. V., Tong, J., Carr, D. B., Boyko, E. J., Leonetti, D. L., McNeely, M. J., Fujimoto, W. Y., & Kahn, S. E. (2009) · Diabetes Care · doi:10.2337/dc08-1478 · Cited by 572
Self-citationThe Diabetes Prevention Program Research Group (2005) · Diabetes · doi:10.2337/diabetes.54.8.2404 · Cited by 446
Cited by
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetes Care · doi:10.2337/dci20-0022 · Cited by 400
Self-citationHemmingsen, B., Gimenez-Perez, G., Mauricio, D., Roqué i Figuls, M., Metzendorf, M.-I., & Richter, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003054.pub4 · Cited by 316
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05181-w · Cited by 203
Self-citationKnowler (2011) · doi:10.1001/archinternmed.2011.367 · Cited by 194
Knowler, W. C. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_16-1 · Cited by 194
Self-citationPrecision medicine in the management of type 2 diabetes
Gloyn, A. L., & Drucker, D. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30052-4 · Cited by 183
Precision medicine in diabetes prevention, classification and management
Xie, F., Chan, J. C., & Ma, R. C. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12830 · Cited by 97
Metformin for diabetes prevention: update of the evidence base
Gottwald‐Hostalek, U., & Campbell, I. W. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1955667 · Cited by 81
Hemmingsen, B., Sonne, D. P., Metzendorf, M.-I., & Richter, B. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012151.pub2 · Cited by 60
Lifestyle precision medicine: the next generation in type 2 diabetes prevention?
Mutie, P. M., Giordano, G. N., & Franks, P. W. (2017) · BMC Medicine · doi:10.1186/s12916-017-0938-x · Cited by 73
“found that these did not influence the effects of lifestyle on insulin sensitivity after 1 year of intervention [125].”
BackgroundSelf-citationMadsen, K. S., Chi, Y., Metzendorf, M.-I., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008558.pub2 · Cited by 70
Precision Medicine in Diabetes: Is It Time?
Florez, J. C. (2016) · Diabetes Care · doi:10.2337/dc16-0586 · Cited by 57
Self-citationGenetic Risk, a Healthy Lifestyle, and Type 2 Diabetes: the Dongfeng-Tongji Cohort Study
Han, X., Wei, Y., Hu, H., Wang, J., Li, Z., Wang, F., Long, T., Yuan, J., Yao, P., Wei, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz325 · Cited by 51
DiBenedetto, J. C., Blum, N. M., O’Brian, C. A., Kolb, L. E., & Lipman, R. D. (2016) · The Diabetes Educator · doi:10.1177/0145721716668415 · Cited by 28
“An important factor resulting in the broader definition for the target population, in whom screening would be of benefit, was the strong evidence base demonstrating the efficacy of lifestyle and/or drug interventions programs to significantly reduce the rate of diabetes onset.(5-15) Lifestyle intervention for glycemic…”
BackgroundLiu, Y., Jiang, X., & Chen, X. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0609-0 · Cited by 31
Raghavan, S., Jablonski, K., Delahanty, L. M., Maruthur, N. M., Leong, A., Franks, P. W., Knowler, W. C., Florez, J. C., & Dabelea, D. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14309 · Cited by 29
“While improvement of insulin sensitivity and insulin secretion from ILS is a predictor of diabetes risk reduction in the DPP,(31) changes in insulin sensitivity from ILS did not vary across levels of insulin resistance genetic risk.(17) Although the DPP demonstrated the efficacy of ILS on reducing diabetes risk in a h…”
BackgroundMethodInfluentialSelf-citationDemir, A. K., Şahin, Ş., Kaya, S. U., Bütün, İ., Çıtıl, R., Önder, Y., Taşlıyurt, T., Demir, O., Deveci, K., & Kutlutürk, F. (2020) · African Health Sciences · doi:10.4314/ahs.v20i1.33 · Cited by 26
Leveraging Genetics to Advance Type 2 Diabetes Prevention
Florez, J. C. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002102 · Cited by 25
“Lifestyle interventions are successful across the full range of genetic risk (Fig 1) [6,7] and can also reduce cardiovascular mortality if given enough time [8].”
BackgroundSelf-citationTODAY Study Group, TODAY Study Group, HIGGINS, J. A., Chernausek, S. D., ghormli, L. K. E., ISGANAITIS, E. M., Kelsey, M. M., Marcus, M. D., McKay, S. V., Siska, M., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0784 · Cited by 22
Treatment with EV-miRNAs Alleviates Obesity-Associated Metabolic Dysfunction in Mice
Castaño, C., Meza‐Ramos, A., Batlle, M., Guasch, E., Novials, A., & Párrizas, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314920 · Cited by 22
“A high-calorie diet causes metabolic inflexibility, whereas physical activity favors metabolic flexibility, improves cardiorespiratory fitness (CRF) [5], and delays the onset of T2D, even outperforming the effects of established drugs such as metformin [6].”
BackgroundQiu, J., Li, J., Xu, S. M., Zeng, H., Zhang, Y., Yang, S., Fang, L., Huang, J., Zhou, H., Feng, J., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02674-z · Cited by 19
“In recent years, the potential of lifestyle modifications to off-set the adverse effects of IR has emerged as a compelling research area [53, 54].”
Zhao, C., Zhu, P., Shen, Q., & Jin, L. (2017) · Medicine · doi:10.1097/md.0000000000009473 · Cited by 19
Ramezankhani, A., Habibi-Moeini, A. S., Zadeh, S. S. T., Azizi, F., & Hadaegh, F. (2022) · Journal of Global Health · doi:10.7189/jogh.12.04068 · Cited by 17
Lipid and inflammatory biomarker profiles in early insulin resistance
Marcelino-Rodríguez, I., García, J. O., Sánchez, J. J. A., González, D. A., Coello, S. D., Díaz, B. B., Gannar, F., Pérez, M. D. C. R., Elosúa, R., & de León, A. C. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0885-6 · Cited by 16
Ligthart, S., Hasbani, N. R., Ahmadizar, F., van Herpt, T. T. W., Leening, M. J. G., Uitterlinden, A. G., Sijbrands, E. J. G., Morrison, A. C., Boerwinkle, E., Pankow, J. S., et al. (2021) · Diabetic Medicine · doi:10.1111/dme.14639 · Cited by 14
Srinivasan, S., Jablonski, K. A., Knowler, W. C., Dagogo-Jack, S. E., Kahn, S. E., Boyko, E. J., Bray, G. A., Horton, E. S., Hivert, M., Goldberg, R. B., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00069 · Cited by 13
Self-citationBillings, L. K., Jablonski, K. A., Pan, Q., Florez, J. C., Franks, P. W., Goldberg, R. B., Hivert, M.-F., Kahn, S. E., Knowler, W. C., Lee, C. G., et al. (2024) · Diabetes · doi:10.2337/db23-0761 · Cited by 11
Self-citationBrogan, R. J., Rooyackers, O., Phillips, B. E., Twelkmeyer, B., Ross, L. M., Atherton, P. J., Kraus, W. E., Timmons, J. A., & Gallagher, I. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf285 · Cited by 11
The Genetics of Type 2 Diabetes in Youth: Where We Are and the Road Ahead
Srinivasan, S., & Todd, J. N. (2022) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2022.05.044 · Cited by 10
Ghildayal, N., Allard, C., Blais, K., Doyon, M., Arguin, M., Bouchard, L., Perron, P., & Hivert, M. (2022) · Pediatric Obesity · doi:10.1111/ijpo.12982 · Cited by 8
Self-citationDashti, H. S., Levy, D. E., Hivert, M., Alimenti, K., McCurley, J. L., Saxena, R., & Thorndike, A. N. (2021) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqab303 · Cited by 8
Self-citationThe Continuing Evolution of Precision Health in Type 2 Diabetes: Achievements and Challenges
Lin, Y., & Wessel, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1137-2 · Cited by 7
Heianza, Y., & Qi, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00029-1 · Cited by 6
Bianchi, C., Prato, S. D., Rothberg, A. E., & Nauck, M. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70674 · Cited by 3
Precision Medicine in Endocrinology Practice
Meybodi, H. R. A., Hasanzad, M., Sarhangi, N., & Larijani, B. A. (2022) · Springer eBooks · doi:10.1007/978-981-19-5082-7_5 · Cited by 2
Perreault, L. (2017) · Contemporary diabetes · doi:10.1007/978-3-319-61013-9_2 · Cited by 1
Self-citationVenditti, E. M., Emery, R. L., & Kolko, R. P. (2020) · Springer eBooks · doi:10.1007/978-3-030-33286-0_19 · Cited by 1
Precision medicine in diabetes - current trends and future directions. Is the future now?
Szczerbiński, Ł., & Florez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00021-6 · Cited by 1
Self-citationZammit, M., Agius, R., Fava, S., Vassallo, J., & Pace, N. P. (2024) · Acta Diabetologica · doi:10.1007/s00592-023-02230-9 · Cited by 1
Prediction and progression of type 2 diabetes using molecular characterized signatures
Dong, Q. (2025) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.35978
Metadata
- Authors
- Hivert, M.-F., Christophi, C. A., Franks, P. W., Jablonski, K. A., Ehrmann, D. A., Kahn, S. E., Horton, E. S., Pollin, T. I., Mather, K. J., Perreault, L., Barrett-Connor, E., Knowler, W. C., Florez, J. C., & for the Diabetes Prevention Program Research Group
- Affiliations
- Université de Sherbrooke (CA)
- George Washington University (US)
- Harvard University (US)
- University of Chicago (US)
- University of Washington (US)
- Joslin Diabetes Center (US)
- University of Maryland, Baltimore (US)
- Indiana University Indianapolis (US)
- University of Colorado Anschutz (US)
- University of California San Diego (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Diabetes Research Center (Diabetes Unit), Department of Medicine, Massachusetts General Hospital, Boston, MA
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-11-02
- Volume
- 65
- Issue
- 2
- Pages
- 520-526
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC4747453
- OpenAlex
- W2185432117
- Cited by
- 38
- References
- 22
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 6 · 2021: 4 · 2020: 5 · 2019: 3 · 2018: 2 · 2017: 6 · 2016: 5
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-48489)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Keywords
- insulin resistance, polygenic risk score, metformin, lifestyle intervention, insulin sensitivity index, type 2 diabetes prevention, Diabetes Prevention Program, genetic burden, treatment response heterogeneity
- MeSH terms
- Adult, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Metformin, Middle Aged, Risk Factors, United States, Genetic Variation, Risk Assessment, Genetic Predisposition to Disease, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.